Therapeutics

AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system. AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases.

At 7TM Pharma we focus on developing our pipeline of clinical assets forward with a primary therapeutic focus in obesity, related metabolic diseases and gastrointestinal diseases. These are areas with obvious unmet medicinal needs. According to the WHO, there are more than 400 million clinically obese people worldwide, and the number is growing rapidly.

Our organization supports the preclinical and clinical activities within our internal as well as external collaborative programs, and actively seek collaborative opportunities for our programs.